The role of cell lines in the study of neuroendocrine tumors

Neuroendocrinology

Volumn 96, Issue 3, 2012, Pages 173-187

  Grozinsky Glasberg, Simona ^a   Shimon, Ilan ^b,c   Rubinfeld, Hadara ^b,c  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b RABIN MEDICAL CENTER   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

Carcinoid; Cell culture; Cell line; Medullary thyroid cancer; Neuroendocrine tumor; Pancreas; Pheochromocytomas

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; ANGIOPEPTIN; ANTINEOPLASTIC AGENT; BORTEZOMIB; BREFELDIN A; CHIR 265; EVEROLIMUS; GEFITINIB; IMATINIB; NSC 95397; OCTREOTIDE; RAPAMYCIN; SANGUINARINE; UNCLASSIFIED DRUG;

ANTIPROLIFERATIVE ACTIVITY; CANCER CELL CULTURE; CANCER INHIBITION; CELL HETEROGENEITY; CELL STRAIN BETA TC3; CELL STRAIN BON1; CELL STRAIN CM; CELL STRAIN CNDT2; CELL STRAIN COLO320DM; CELL STRAIN CTN3; CELL STRAIN GOT1; CELL STRAIN HUNET; CELL STRAIN INS1; CELL STRAIN KNA; CELL STRAIN KRJ I; CELL STRAIN MIN6; CELL STRAIN MPC; CELL STRAIN MTC F; CELL STRAIN MTC SK; CELL STRAIN NCI H727; CELL STRAIN P STS; CELL STRAIN PC12; CELL STRAIN RIN; CELL STRAIN STC 1; CELL STRAIN TT; DRUG MEGADOSE; DRUG POTENCY; EXPERIMENTAL STUDY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; NEUROENDOCRINE TUMOR; NONHUMAN; PRIORITY JOURNAL; REVIEW; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL PROLIFERATION; HORMONES; HUMANS; NEUROENDOCRINE TUMORS;

EID: 84870236930     PISSN: 00283835     EISSN: 14230194     Source Type: Journal    
DOI: 10.1159/000338793     Document Type: Review

References (122)

1. Oberg K: Neuroendocrine tumors of the gastrointestinal tract: Recent advances in molecular genetics, diagnosis, and treatment. Curr Opin Oncol 2005; 17: 386-391. (Pubitemid 40904429)
2. Caplin ME, Buscombe JR, Hilson AJ, Jones AL, Watkinson AF, Burroughs AK: Carcinoid tumour. Lancet 1998; 352: 799-805. (Pubitemid 128717532)
3. Rindi G, Wiedenmann B: Neuroendocrine neoplasms of the gut and pancreas: New insights. Nat Rev Endocrinol 2011; 8: 54-64.
4. Gaur P, Sceusi EL, Samuel S, et al: Identification of cancer stem cells in human gastrointestinal carcinoid and neuroendocrine tumors. Gastroenterology 2011; 141: 1728-1737.
5. Ganim RB, Norton JA: Recent advances in carcinoid pathogenesis, diagnosis and management. Surg Oncol 2000; 9: 173-179. (Pubitemid 32722028)
6. Solcia E, Klöppel G, Sobin H: Histological typing of endocrine tumours. World Health Organization International Histological Classification of Tumours. Berlin, Springer, 2000.
7. Oberg K: Management of neuroendocrine tumours. Ann Oncol 2004; 15(suppl 4):iv293-iv298. (Pubitemid 39585350)
8. Oberg K, Kvols L, Caplin M, et al: Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol 2004; 15: 966-973. (Pubitemid 39004355)
9. Witkowski JA: Experimental pathology and the origins of tissue culture: Leo Loeb's contribution. Med Hist 1983; 27: 269-288.
10. Oppenheimer JM: The Fielding H. Garrison Lecture: Taking things apart and putting them together again. Bull Hist Med 1978; 52: 149-161. (Pubitemid 9123055)
11. Potash J, Anderson KC: What's Your Line? Clin Cancer Res 2009; 15: 4251.
12. Rockwell S: In vivo-in vitro tumour cell lines: Characteristics and limitations as models for human cancer. Br J Cancer Suppl 1980; 4: 118-122. (Pubitemid 10047957)
13. Leotlela PD, Jauch A, Holtgreve-Grez H, Thakker RV: Genetics of neuroendocrine and carcinoid tumours. Endocr Relat Cancer 2003; 10: 437-450. (Pubitemid 38094880)
14. Ooi GT, Tawadros N, Escalona RM: Pituitary cell lines and their endocrine applications. Mol Cell Endocrinol 2004; 228: 1-21. (Pubitemid 39482516)
15. Kloppel G: Oberndorfer and his successors: From carcinoid to neuroendocrine carcinoma. Endocr Pathol 2007; 18: 141-144. (Pubitemid 351378064)
16. Modlin IM, Lye KD, Kidd M: A 5-decade analysis of 13,715 carcinoid tumors. Cancer 2003; 97: 934-959. (Pubitemid 36173145)
17. Sjolund K, Sanden G, Hakanson R, Sundler F: Endocrine cells in human intestine: An immunocytochemical study. Gastroenterology 1983; 85: 1120-1130. (Pubitemid 13007805)
18. Cetin Y, Kuhn M, Kulaksiz H, et al: Enterochromaffin cells of the digestive system: Cellular source of guanylin, a guanylate cyclaseactivating peptide. Proc Natl Acad Sci USA 1994; 91: 2935-2939. (Pubitemid 24130149)
19. Betton GR, Dormer CS, Wells T, Pert P, Price CA, Buckley P: Gastric ECL-cell hyperplasia and carcinoids in rodents following chronic administration of H2-antagonists SK&F 93479 and oxmetidine and omeprazole. Toxicol Pathol 1988; 16: 288-298.
20. Gronstad KO, Nilsson O, Dahlstrom A, Skolnik G, Ahlman H: Adrenergic control of serotonin release from carcinoid tumor cells in vitro and in vivo. J Surg Res 1987; 42: 141-146. (Pubitemid 17024829)
21. Nilsson O, Ahlman H, Ericson LE, Skolnik G, Dahlstrom A: Release of serotonin from human carcinoid tumor cells in vitro and grown in the anterior eye chamber of the rat. Cancer 1986; 58: 676-684. (Pubitemid 16072070)
22. Bulbring E, Lin RC: The effect of intraluminal application of 5-hydroxytryptamine and 5-hydroxytryptophan on peristalsis; the local production of 5-HT and its release in relation to intraluminal pressure and propulsive activity. J Physiol 1958; 140: 381-407.
23. Modlin IM, Kidd M, Latich I, Zikusoka MN, Shapiro MD: Current status of gastrointestinal carcinoids. Gastroenterology 2005; 128: 1717-1751. (Pubitemid 40692562)
24. Kolby L, Bernhardt P, Ahlman H, et al: A transplantable human carcinoid as model for somatostatin receptor-mediated and amine transporter-mediated radionuclide uptake. Am J Pathol 2001; 158: 745-755. (Pubitemid 32158636)
25. Arvidsson Y, Andersson E, Bergstrom A, et al: Amyloid precursor-like protein 1 is differentially upregulated in neuroendocrine tumours of the gastrointestinal tract. Endocr Relat Cancer 2008; 15: 569-581. (Pubitemid 351880844)
26. Zitzmann K, Ruden J, Brand S, et al: Compensatory activation of Akt in response to mTOR and Raf inhibitors- A rationale for dual-Targeted therapy approaches in neuroendocrine tumor disease. Cancer Lett 2010; 295: 100-109.
27. Bernhardt P, Oddstig J, Kolby L, Nilsson O, Ahlman H, Forssell-Aronsson E: Effects of treatment with (177)Lu-DOTA-Tyr(3)-octreotate on uptake of subsequent injection in carcinoid-bearing nude mice. Cancer Biother Radiopharm 2007; 22: 644-653. (Pubitemid 350059001)
28. Kolby L, Bernhardt P, Levin-Jakobsen AM, et al: Uptake of meta-iodobenzylguanidine in neuroendocrine tumours is mediated by vesicular monoamine transporters. Br J Cancer 2003; 89: 1383-1388. (Pubitemid 37368903)
29. Pfragner R, Wirnsberger G, Niederle B, et al: Establishment of a continuous cell line from a human carcinoid of the small intestine (KRJ-I): Characterization and effects of 5-azacytidine on proliferation. Int J Oncol 1996; 8: 513-520. (Pubitemid 26082169)
30. Modlin IM, Kidd M, Pfragner R, Eick GN, Champaneria MC: The functional characterization of normal and neoplastic human enterochromaffin cells. J Clin Endocrinol Metab 2006; 91: 2340-2348. (Pubitemid 43855026)
31. Kalhan A, Gharibi B, Vazquez M, et al: Adenosine A(2A) and A (2B) receptor expression in neuroendocrine tumours: Potential targets for therapy. Purinergic Signal 2011, E-pub ahead of print
32. Siddique ZL, Drozdov I, Floch J, et al: KRJ-I and BON cell lines: Defining an appropriate enterochromaffin cell neuroendocrine tumor model. Neuroendocrinology 2009; 89: 458-470.
33. Kidd M, Eick GN, Modlin IM, Pfragner R, Champaneria MC, Murren J: Further delineation of the continuous human neoplastic enterochromaffin cell line, KRJ-I, and the inhibitory effects of lanreotide and rapamycin. J Mol Endocrinol 2007; 38: 181-192. (Pubitemid 46351602)
34. Svejda B, Kidd M, Kazberouk A, Lawrence B, Pfragner R, Modlin IM: Limitations in small intestinal neuroendocrine tumor therapy by mTor kinase inhibition reflect growth factor-mediated PI3K feedback loop activation via ERK1/2 and AKT. Cancer 2011; 117: 4141-4154.
35. Rokstad AM, Gustaffson BI, Espevik T, et al: Microencapsulation of small intestinal neuroendocrine neoplasm cells for tumor model studies. Cancer Sci 2012, DOI: 10.1111/ j.1349-7006.2012.02282.x.
36. Svejda B, Aquiriano-Moser V, Sturm S, et al: Anticancer activity of novel plant extracts from Trailliaedoxa gracilis (W. W. Smith & Forrest) in human carcinoid KRJ-I Cells. Anticancer Res 2012; 30: 55-64.
37. Rindi G, Grant SG, Yiangou Y, et al: Development of neuroendocrine tumors in the gastrointestinal tract of transgenic mice. Heterogeneity of hormone expression. Am J Pathol 1990; 136: 1349-1363. (Pubitemid 20210334)
38. Hopfner M, Sutter AP, Beck NI, et al: Metaiodobenzylguanidine induces growth inhibition and apoptosis of neuroendocrine gastrointestinal tumor cells. Int J Cancer 2002; 101: 210-216. (Pubitemid 34970887)
39. Hopfner M, Sutter AP, Gerst B, Zeitz M, Scherubl H: A novel approach in the treatment of neuroendocrine gastrointestinal tumours. Targeting the epidermal growth factor receptor by gefitinib (ZD1839). Br J Cancer 2003; 89: 1766-1775. (Pubitemid 37464152)
40. Nejjari M, Kryza D, Poncet G, et al: In vitro and in vivo studies with [ 18 F]fluorocholine on digestive tumoral cell lines and in an animal model of metastasized endocrine tumor. Nucl Med Biol 2008; 35: 123-130.
41. Poncet G, Villaume K, Walter, et al: Angiogenesis and tumor progression in neuroendocrine digestive tumors. J Surg Res 2008; 154: 68-77.
42. Van Buren G, Rashid A, Yang AD, et al: The development and characterization of a human midgut carcinoid cell line. Clin Cancer Res 2007; 13: 4704-4712. (Pubitemid 47294776)
43. Ellis LM, Samuel S, Sceusi E: Varying opinions on the authenticity of a human midgut carcinoid cell line- letter. Clin Cancer Res 2010; 16: 5365-5366.
44. Quinn LA, Moore GE, Morgan RT, Woods LK: Cell lines from human colon carcinoma with unusual cell products, double minutes, and homogeneously staining regions. Cancer Res 1979; 39: 4914-4924. (Pubitemid 10167719)
45. Park JG, Oie HK, Sugarbaker PH, et al: Characteristics of cell lines established from human colorectal carcinoma. Cancer Res 1987; 47: 6710-6718. (Pubitemid 18019675)
46. Pfragner R, Behmel A, Hoger H, et al: Establishment and characterization of three novel cell lines- P-STS, L-STS, H-STS- derived from a human metastatic midgut carcinoid. Anticancer Res 2009; 29: 1951-1961.
47. Evers BM, Townsend CM Jr, Upp JR, et al: Establishment and characterization of a human carcinoid in nude mice and effect of various agents on tumor growth. Gastroenterology 1991; 101: 303-311.
48. Arany I, Rady P, Evers BM, Tyring SK, Townsend CM Jr: Analysis of multiple molecular changes in human endocrine tumours. Surg Oncol 1994; 3: 153-159. (Pubitemid 24269833)
49. Beauchamp RD, Coffey RJ Jr, Lyons RM, Perkett EA, Townsend CM Jr, Moses HL: Human carcinoid cell production of paracrine growth factors that can stimulate fibroblast and endothelial cell growth. Cancer Res 1991; 51: 5253-5260.
50. Ishizuka J, Hsieh AC, Townsend CM Jr, Thompson JC: Effect of 5-HT3 receptor antagonist (ondansetron) on functioning human pancreatic carcinoid cells. Surg Oncol 1993; 2: 221-225. (Pubitemid 23329720)
51. Ishizuka J, Beauchamp RD, Sato K, Townsend CM Jr, Thompson JC: Novel action of transforming growth factor beta 1 in functioning human pancreatic carcinoid cells. J Cell Physiol 1993; 156: 112-118. (Pubitemid 23211269)
52. von Wichert G, Jehle PM, Hoeflich A, et al: Insulin-like growth factor-I is an autocrine regulator of chromogranin A secretion and growth in human neuroendocrine tumor cells. Cancer Res 2000; 60: 4573-4581. (Pubitemid 32103642)
53. Parekh D, Ishizuka J, Townsend CM Jr, et al: Differential effects of sodium butyrate and hexamethylene bisacetamide on growth and secretion of cultured human endocrine tumor cells. Arch Surg 1991; 126: 467-472.
54. Bold RJ, Ishizuka J, Townsend CM Jr, Thompson JC: All- Trans-retinoic acid inhibits growth of human pancreatic cancer cell lines. Pancreas 1996; 12: 189-195.
55. von Mentzer B, Murata Y, Ahlstedt I, Lindstrom E, Martinez V: Functional CRF receptors in BON cells stimulate serotonin release. Biochem Pharmacol 2007; 73: 805-813. (Pubitemid 46237613)
56. Lopez JR, Claessen SM, Macville MV, Albrechts JC, Skogseid B, Speel EJ: Spectral karyotypic and comparative genomic analysis of the endocrine pancreatic tumor cell line BON-1. Neuroendocrinology 2010; 91: 131-141.
57. Duerr EM, Chung DC: Molecular genetics of neuroendocrine tumors. Best Pract Res Clin Endocrinol Metab 2007; 21: 1-14. (Pubitemid 46436730)
58. Fujiki K, Duerr EM, Kikuchi H, et al: Hoxc6 is overexpressed in gastrointestinal carcinoids and interacts with JunD to regulate tumor growth. Gastroenterology 2008; 135: 907-916.
59. Goke R, Barth P, Schmidt A, Samans B, Lankat-Buttgereit B: Programmed cell death protein 4 suppresses CDK1/cdc2 via induction of p21(Waf1/Cip1). Am J Physiol Cell Physiol 2004; 287:C1541-C1546. (Pubitemid 39507671)
60. Fendrich V, Waldmann J, Esni F, et al: Snail and sonic hedgehog activation in neuroendocrine tumors of the ileum. Endocr Relat Cancer 2007; 14: 865-874. (Pubitemid 350074074)
61. Schimmack S, Lawrence B, Svejda B, et al: The clinical implications and biologic relevance of neurofilament expression in gastroenteropancreatic neuroendocrine neoplasms. Cancer 2012;118:2763-2775.
62. Stalberg P, Grimfjard P, Santesson M, et al: Transfection of the multiple endocrine neoplasia type 1 gene to a human endocrine pancreatic tumor cell line inhibits cell growth and affects expression of JunD, delta-like protein 1/preadipocyte factor-1, proliferating cell nuclear antigen, and QM/Jif-1. J Clin Endocrinol Metab 2004; 89: 2326-2337. (Pubitemid 38619871)
63. Ludvigsen E, Stridsberg M, Taylor JE, Culler MD, Oberg K, Janson ET: Subtype selective interactions of somatostatin and somatostatin analogs with sst1, sst2, and sst5 in BON-1 cells. Med Oncol 2004; 21: 285-295. (Pubitemid 39469770)
64. Altomare DA, Testa JR: Perturbations of the AKT signaling pathway in human cancer. Oncogene 2005; 24: 7455-7464. (Pubitemid 41637985)
65. Zitzmann K, De Toni EN, Brand S, et al: The novel mTOR inhibitor RAD001 (everolimus) induces antiproliferative effects in human pancreatic neuroendocrine tumor cells. Neuroendocrinology 2007; 85: 54-60. (Pubitemid 46550026)
66. Pitt SC, Chen H, Kunnimalaiyaan M: Inhibition of phosphatidylinositol 3-kinase/Akt signaling suppresses tumor cell proliferation and neuroendocrine marker expression in GI carcinoid tumors. Ann Surg Oncol 2009; 16: 2936-2942.
67. Yao JC, Zhang JX, Rashid A, et al: Clinical and in vitro studies of imatinib in advanced carcinoid tumors. Clin Cancer Res 2007; 13: 234-240. (Pubitemid 46121874)
68. Lankat-Buttgereit B, Horsch D, Barth P, Arnold R, Blocker S, Goke R: Effects of the tyrosine kinase inhibitor imatinib on neuroendocrine tumor cell growth. Digestion 2005; 71: 131-140. (Pubitemid 40910932)
69. Larsson DE, Wickstrom M, Hassan S, Oberg K, Granberg D: The cytotoxic agents NSC-95397, brefeldin A, bortezomib and sanguinarine induce apoptosis in neuroendocrine tumors in vitro. Anticancer Res 2010; 30: 149-156.
70. Imam H, Eriksson B, Lukinius A, et al: Induction of apoptosis in neuroendocrine tumors of the digestive system during treatment with somatostatin analogs. Acta Oncol 1997; 36: 607-614. (Pubitemid 27512573)
71. Moreno A, Akcakanat A, Munsell MF, Soni A, Yao JC, Meric-Bernstam F: Antitumor activity of rapamycin and octreotide as single agents or in combination in neuroendocrine tumors. Endocr Relat Cancer 2008; 15: 257-266. (Pubitemid 351449744)
72. Sun LC, Mackey LV, Luo J, Fuselier JA, Coy DH: Targeted chemotherapy using a cytotoxic somatostatin conjugate to inhibit tumor growth and metastasis in nude mice. Clin Med Oncol 2008; 2: 491-499.
73. Carrington CA, Rubery ED, Pearson EC, Hales CN: Five new insulin-producing cell lines with differing secretory properties. J Endocrinol 1986; 109: 193-200. (Pubitemid 16081647)
74. Baroni MG, Cavallo MG, Mark M, Monetini L, Stoehrer B, Pozzilli P: Beta-cell gene expression and functional characterisation of the human insulinoma cell line CM. J Endocrinol 1999; 161: 59-68. (Pubitemid 29170192)
75. Santerre RF, Cook RA, Crisel RM, et al: Insulin synthesis in a clonal cell line of simian virus 40-Transformed hamster pancreatic beta cells. Proc Natl Acad Sci USA 1981; 78: 4339-4343. (Pubitemid 11010201)
76. Gazdar AF, Chick WL, Oie HK, et al: Continuous, clonal, insulin- And somatostatinsecreting cell lines established from a transplantable rat islet cell tumor. Proc Natl Acad Sci USA 1980; 77: 3519-3523. (Pubitemid 10012266)
77. Brand SJ, Wang TC: Gastrin gene expression and regulation in rat islet cell lines. J Biol Chem 1988; 263: 16597-16603. (Pubitemid 18268837)
78. Sjoholm A: Regulation of insulinoma cell proliferation and insulin accumulation by peptides and second messengers. Ups J Med Sci 1995; 100: 201-216. (Pubitemid 3024536)
79. von Blankenfeld G, Turner J, Ahnert-Hilger G, et al: Expression of functional GABAA receptors in neuroendocrine gastropancreatic cells. Pflugers Arch 1995; 430: 381-388.
80. Bartz C, Ziske C, Wiedenmann B, Moelling K: P53 tumour suppressor gene expression in pancreatic neuroendocrine tumour cells. Gut 1996; 38: 403-409. (Pubitemid 26075537)
81. Burt JM, Nelson TK, Simon AM, Fang JS: Connexin 37 profoundly slows cell cycle progression in rat insulinoma cells. Am J Physiol Cell Physiol 2008; 295:C1103-C1112. (Pubitemid 352790343)
82. Jonnakuty C, Gragnoli C: Karyotype of the human insulinoma CM cell line- Beta cell model in vitro? J Cell Physiol 2007; 213: 661-662. (Pubitemid 350058259)
83. Grozinsky-Glasberg S, Franchi G, Teng M, et al: Octreotide and the mTOR inhibitor RAD001 (everolimus) block proliferation and interact with the Akt-mTOR-p70S6K pathway in a neuro-Endocrine tumour cell line. Neuroendocrinology 2008; 87: 168-181. (Pubitemid 351563811)
84. Karhoff D, Sauer S, Schrader J, et al: Rap1/BRaf signaling is activated in neuroendocrine tumors of the digestive tract and Raf kinase inhibition constitutes a putative therapeutic target. Neuroendocrinology 2007; 85: 45-53. (Pubitemid 46550025)
85. Brom M, Oyen WJ, Joosten L, Gotthardt M, Boerman OC: 68Ga-labelled exendin-3, a new agent for the detection of insulinomas with PET. Eur J Nucl Med Mol Imaging 2010; 37: 1345-1355.
86. Minami K, Yano H, Miki T, et al: Insulin secretion and differential gene expression in glucose-responsive and-unresponsive MIN6 sublines. Am J Physiol Endocrinol Metab 2000; 279:E773-E781.
87. Iino S, Abeyama K, Kawahara K, et al: The antimetastatic role of thrombomodulin expression in islet cell-derived tumors and its diagnostic value. Clin Cancer Res 2004; 10: 6179-6188. (Pubitemid 39287524)
88. Ohkawara H, Miyazaki J, Naqakawa Y, Sato S, Karibe S, Akaike T: Xenoimplantation using a diffusion chamber with a B-cell line (MIN6) as a bioartificial endocrine pancreas (Bio-AEP). Cell Transplant 1996; 5(suppl 1):71-73.
89. Efrat S, Surana M, Fleischer N: Glucose induces insulin gene transcription in a murine pancreatic beta-cell line. J Biol Chem 1991; 266: 11141-11143. (Pubitemid 21906923)
90. Galbiati F, Polastri L, Gregori S, et al: Antitumorigenic and antiinsulinogenic effects of calcitriol on insulinoma cells and solid betacell tumors. Endocrinology 2002; 143: 4018-4030. (Pubitemid 35244381)
91. Tillotson LG, Lodestro C, Hocker M, Wiedenmann B, Newcomer CE, Reid LM: Isolation, maintenance, and characterization of human pancreatic islet tumor cells expressing vasoactive intestinal peptide. Pancreas 2001; 22: 91-98. (Pubitemid 32046222)
92. Brandt DW, Pandol SJ, Deftos LJ: Calciumstimulated parathyroid hormone-like protein secretion: Potentiation through a protein kinase-C pathway. Endocrinology 1991; 128: 2999-3004.
93. Stepien T, Sacewicz M, Lawnicka H, et al: Stimulatory effect of growth hormone-releasing hormone (GHRH(1-29)NH2) on the proliferation, VEGF and chromogranin A secretion by human neuroendocrine tumor cell line NCI-H727 in vitro. Neuropeptides 2009; 43: 397-400.
94. Pitt SC, Chen H, Kunnimalaiyaan M: Phosphatidylinositol 3-kinase-Akt signaling in pulmonary carcinoid cells. J Am Coll Surg 2009; 209: 82-88.
95. Greenblatt DY, Vaccaro AM, Jaskula-Sztul R, et al: Valproic acid activates notch-1 signaling and regulates the neuroendocrine phenotype in carcinoid cancer cells. Oncologist 2007; 12: 942-951. (Pubitemid 47359136)
96. Lee M, Draoui M, Zia F, et al: Epidermal growth factor receptor monoclonal antibodies inhibit the growth of lung cancer cell lines. J Natl Cancer Inst Monogr 1992; 13: 117-123.
97. Gilbert JA, Adhikari LJ, Lloyd RV, et al: Molecular markers for novel therapies in neuroendocrine (carcinoid) tumors. Endocr Relat Cancer 2010; 17: 623-636.
98. Zabel M, Grzeszkowiak J: Characterisation of thyroid medullary carcinoma TT cell line. Histol Histopathol 1997; 12: 283-289. (Pubitemid 27106938)
99. Zatelli MC, Tagliati F, Taylor JE, Rossi R, Culler MD, degli Uberti EC: Somatostatin receptor subtypes 2 and 5 differentially affect proliferation in vitro of the human medullary thyroid carcinoma cell line tt. J Clin Endocrinol Metab 2001; 86: 2161-2169. (Pubitemid 32472934)
100. Zatelli MC, Tagliati F, Piccin D, et al: Somatostatin receptor subtype 1-selective activation reduces cell growth and calcitonin secretion in a human medullary thyroid carcinoma cell line. Biochem Biophys Res Commun 2002; 297: 828-834.
101. Grozinsky-Glasberg S, Rubinfeld H, Nordenberg Y, et al: The rapamycin-derivative RAD001 (everolimus) inhibits cell viability and interacts with the Akt-mTOR-p70S6K pathway in human medullary thyroid carcinoma cells. Mol Cell Endocrinol 2010; 5;315: 87-94.
102. Zhu W, Hai T, Ye L, Cote GJ: Medullary thyroid carcinoma cell lines contain a self-renewing CD133+ population that is dependent on ret proto-oncogene activity. J Clin Endocrinol Metab 2010; 95: 439-444.
103. Stein R, Juweid M, Mattes MJ, Goldenberg DM: Carcinoembryonic antigen as a target for radioimmunotherapy of human medullary thyroid carcinoma: Antibody processing, targeting, and experimental therapy with 131I and 90Y labeled MAbs. Cancer Biother Radiopharm 1999; 14: 37-47. (Pubitemid 29157733)
104. Stein R, Goldenberg DM: A humanized monoclonal antibody to carcinoembryonic antigen, labetuzumab, inhibits tumor growth and sensitizes human medullary thyroid cancer xenografts to dacarbazine chemotherapy. Mol Cancer Ther 2004; 3: 1559-1564. (Pubitemid 40136711)
105. Jin N, Jiang T, Rosen DM, Nelkin BD, Ball DW: Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer. Clin Cancer Res 2011; 17: 6482-6489.
106. Kraeber-Bodere F, Sai-Maurel C, Campion L, et al: Enhanced antitumor activity of combined pretargeted radioimmunotherapy and paclitaxel in medullary thyroid cancer xenograft. Mol Cancer Ther 2002; 1: 267-274.
107. Kraeber-Bodere F, Bodet-Milin C, Niaudet C, et al: Comparative toxicity and efficacy of combined radioimmunotherapy and antiangiogenic therapy in carcinoembryonic antigen-Expressing medullary thyroid cancer xenograft. J Nucl Med 2010; 51: 624-631.
108. Petrangolini G, Cuccuru G, Lanzi C, et al: Apoptotic cell death induction and angiogenesis inhibition in large established medullary thyroid carcinoma xenografts by Ret inhibitor RPI-1. Biochem Pharmacol 2006; 72: 405-414. (Pubitemid 44061744)
109. Cuccuru G, Lanzi C, Cassinelli G, et al: Cellular effects and antitumor activity of RET inhibitor RPI-1 on MEN2A-associated medullary thyroid carcinoma. J Natl Cancer Inst 2004; 96: 1006-1014. (Pubitemid 39162643)
110. Pfragner R, Hofler H, Behmel A, Ingolic E, Walser V: Establishment and characterization of continuous cell line MTC-SK derived from a human medullary thyroid carcinoma. Cancer Res 1990; 50: 4160-4166. (Pubitemid 20225645)
111. Kaczirek K, Schindl M, Weinhausel A, et al: Cytotoxic activity of camptothecin and paclitaxel in newly established continuous human medullary thyroid carcinoma cell lines. J Clin Endocrinol Metab 2004; 89: 2397-2401. (Pubitemid 38619881)
112. Matoso A, Zhou Z, Hayama R, Flesken-Nikitin A, Nikitin AY: Cell lineage-specific interactions between Men1 and Rb in neuroendocrine neoplasia. Carcinogenesis 2008; 29: 620-628. (Pubitemid 351404880)
113. Tischler AS, Greene LA: Morphologic and cytochemical properties of a clonal line of rat adrenal pheochromocytoma cells which respond to nerve growth factor. Lab Invest 1978; 39: 77-89. (Pubitemid 8390099)
114. Califano D, D'Alessio A, Colucci-D'Amato GL, et al: A potential pathogenetic mechanism for multiple endocrine neoplasia type 2 syndromes involves ret-induced impairment of terminal differentiation of neuroepithelial cells. Proc Natl Acad Sci USA 1996; 93: 7933-7937. (Pubitemid 26277142)
115. Connolly R, Gates D, Loh N, et al: Cox-2 promotes chromogranin A expression and bioactivity: Evidence for a prostaglandin E2-dependent mechanism and the involvement of a proximal cyclic adenosine 5-monophosphate-responsive element. Endocrinology 2007; 148: 4310-4317. (Pubitemid 47295689)
116. Alesci S, Perera SM, Lai EW, et al: Adenoviral gene transfer in bovine adrenomedullary and murine pheochromocytoma cells: Potential clinical and therapeutic relevance. Endocrinology 2007; 148: 3900-3907. (Pubitemid 47105833)
117. Zielke A, Bresalier RS, Siperstein AE, Clark OH, Rothmund M, Duh QY: A unique allogenic model of metastatic pheochromocytoma: PC12 rat pheochromocytoma xenografts to nude mice and establishment of metastases-derived PC12 variants. Clin Exp Metastasis 1998; 16: 341-352. (Pubitemid 28255529)
118. Soto-Montenegro ML, Vaquero JJ, Garcia-Villalba C, Desco M, Canamero M, Velikyan I: Molecular imaging of pheochromocytoma with 68Ga-DOTATOC-PET: Comparative pilot study with neuropancreatic tumor. Poster Presentation (P370) World Molecular Imaging Congress, San Diego, 2011.
119. Powers JF, Evinger MJ, Tsokas P, et al: Pheochromocytoma cell lines from heterozygous neurofibromatosis knockout mice. Cell Tissue Res 2000; 302: 309-320.
120. Alesci S, Perera SM, Lai EW, et al: Adenoviral gene transfer in bovine adrenomedullary and murine pheochromocytoma cells: Potential clinical and therapeutic relevance. Endocrinology 2007; 148: 3900-3907. (Pubitemid 47105833)
121. Lai EW, Joshi BH, Martiniova L, et al: Overexpression of interleukin-13 receptor-alpha2 in neuroendocrine malignant pheochromocytoma: A novel target for receptor directed anti-cancer therapy. J Clin Endocrinol Metab 2009; 94: 2952-2957.
122. Pfragner R, Behmel A, Smith DP, et al: First continuous human pheochromocytoma cell line: KNA. Biological, cytogenetic and molecular characterization of KNA cells. J Neurocytol 1998; 27: 175-186. (Pubitemid 28253068)